Treatment must be focused on several targets: glycemic control, bulk reductions of LDL cholesterol, and shifting LDL particle size. Aggressive treatment and reversal of dyslipidemias is a proven prevention for coronary events in patients with type 2 diabetes. Glycemic control with diet, oral ...
Novartis' dyslipidemia treatment Leqvio Prefilled Syringe (ingredient: inclisiran sodium) won regulatory approval in Korea. The Ministry of Food and Drug Safety said on Thursday that it granted marketing approval for Leqvio, an injectable siRNA for the treatment of dyslipidemia, as an adjunct to di...
Nuciferine, an alkaloid extracted from lotus leaf [132], the main bioactive compounds for dyslipidemia treatment, can regulate the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver to treat dyslipidemia and NAFLD ...
therapy for dyslipidemias. The fibrates work preferentially on the liver to reduce triglyceride synthesis and very low-density lipoprotein (VLDL) production. Fibrates also stimulate the uptake and metabolism of VLDL from the plasma, which can lead to increased LDL levels in patients who have very h...
Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome an...
Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapiesdoi:10.1007/s40265-015-0428-4Coronary heart disease (CHD) is the leading cause of death in most countries, with the high prevalence currently driven by dual epidemics of obesity and ...
The prevention of cardiovascular disease in adulthood begins with the diagnosis and treatment of dyslipidemia in childhood and adolescence. After brief reviews of the prevalence and causes of dyslipidemia, this chapter focuses on the recommendations for screening and an evidence-based approach to the man...
Dyslipidemia in Treatment Nave HIV 来自 Semantic Scholar 喜欢 0 阅读量: 3 作者: R Sivakumar 摘要: INTRODUCTION:The natural history of human immunodeficiency virus (HIV) infection changes with the use of highly active antiretroviral therapy (HAART) through reduction in risks of death associated with...
Dyslipidemia and Cardiovascular Risk: Lipid Ratios as Risk Factors for Cardiovascular Disease, Dyslipidemia - From Prevention to Treatment, Prof. Roya Kelishadi (Ed.), ISBN: 978-953- 307-904-2.Telmo Pereira. Dyslipidemia and cardiovascular risk: Lipid ratios as risk factors for cardiovascular ...
Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular MortalityDyslipidemia is one of the common risk factors for NAFLD and is associated with cardiovascular (CV) mortality, which is the most common cause of death in NAFLD. Lipid锕峯wering agents (LLAs) are used to...